Los Angeles Capital Management LLC bought a new position in Selecta Biosciences, Inc. (NASDAQ:SELB) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 10,777 shares of the company’s stock, valued at approximately $45,000.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Axiom Investment Management LLC bought a new stake in shares of Selecta Biosciences in the first quarter worth about $45,000. BNP Paribas Arbitrage SA grew its stake in shares of Selecta Biosciences by 39.0% in the first quarter. BNP Paribas Arbitrage SA now owns 17,955 shares of the company’s stock worth $81,000 after purchasing an additional 5,035 shares during the last quarter. US Bancorp DE bought a new stake in shares of Selecta Biosciences in the first quarter worth about $113,000. Hancock Whitney Corp bought a new stake in shares of Selecta Biosciences in the first quarter worth about $114,000. Finally, Personal CFO Solutions LLC bought a new stake in shares of Selecta Biosciences in the second quarter worth about $122,000. 45.09% of the stock is currently owned by institutional investors.
In other Selecta Biosciences news, Director Timothy C. Barabe bought 9,000 shares of the stock in a transaction dated Wednesday, August 18th. The stock was purchased at an average cost of $4.00 per share, for a total transaction of $36,000.00. Following the completion of the acquisition, the director now owns 190,013 shares of the company’s stock, valued at $760,052. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 24.00% of the stock is currently owned by company insiders.
SELB stock opened at $4.01 on Wednesday. The firm has a 50 day moving average price of $3.95 and a 200-day moving average price of $4.02. Selecta Biosciences, Inc. has a 52-week low of $1.47 and a 52-week high of $5.70. The firm has a market capitalization of $461.47 million, a price-to-earnings ratio of -8.91 and a beta of 1.02.
Selecta Biosciences (NASDAQ:SELB) last released its earnings results on Wednesday, August 11th. The company reported $0.04 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.12) by $0.16. The business had revenue of $19.66 million for the quarter, compared to analysts’ expectations of $10.83 million. Analysts forecast that Selecta Biosciences, Inc. will post -0.12 earnings per share for the current year.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. It produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation.
Recommended Story: Conference Calls and Individual Investors
Want to see what other hedge funds are holding SELB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Selecta Biosciences, Inc. (NASDAQ:SELB).
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.